SCHEMBL20138236

SCHEMBL20138236

Cc1nc2ccccn2c1CN1C(=O)COc2ccc(-c3ccc4c(c3)C(=O)NCC4)nc21

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.37
PARP10 Q53GL7 5/20 0.33
PARP1 P09874 3/20 0.33
ROCK2 O75116 1/20 0.32
PARP11 Q9NR21 3/20 0.31
PDPK1 O15530 1/20 0.31
MTOR P42345 1/20 0.31
CD274 Q9NZQ7 1/20 0.31
BRD4 O60885 1/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
LMNA P02545 1/20 0.31
HTT P42858 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
MAPKAPK2 P49137 1/20 0.31
SSTR5 P35346 1/20 0.31
NPC1 O15118 1/20 0.31
ALDH1A1 P00352 1/20 0.31
TP53 P04637 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20138255 0.86 MAPK1 (0.36) MAPK1PARP10PARP1MTORCD274
SCHEMBL20138307 0.82 MAPK1 (0.42) MAPK1PARP10PARP1PARP11PDPK1
SCHEMBL20964736 0.81 CDK4 (0.38) MAPK1PARP10PARP1PARP11CD274
SCHEMBL20138109 0.80 MAPK1 (0.43) MAPK1PARP10PARP1PARP11MTOR
SCHEMBL20137967 0.79 MAPK1 (0.43) MAPK1PARP10PARP1MTORCD274
SCHEMBL20138143 0.77 SSTR5 (0.38) MAPK1SMN1; SMN2LMNAHTTL3MBTL1
SCHEMBL20138207 0.71 SSTR5 (0.36) MAPK1SMN1; SMN2LMNAHTTL3MBTL1
SCHEMBL20138260 0.71 MAPK1 (0.41) MAPK1PARP10PARP1MTORCD274
SCHEMBL18305411 0.69 SLC2A1 (0.43) MAPK1SMN1; SMN2NPC1ALDH1A1TP53
SCHEMBL20138126 0.69 SLC2A1 (0.40) MAPK1SMN1; SMN2NPC1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10287299-B2 Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity UCB BIOPHARMA SPRL (BE) 2019-05-14 US disclosed
US-20180134728-A1 Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity UCB S.A. (BE) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134728-A1 Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity TNF, NFKBIA, TNFRSF1A MAPK1 1235/4885PARP10 1687/4885PARP1 1553/4885
US-10287299-B2 Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity TNF, TNFRSF1A, NFKBIA MAPK1 1268/4885PARP10 3857/4885PARP1 2142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.